Chronic pain conditions are prevalent and cause a significant burden of disease. Intravenous lidocaine infusions have been reported to have an analgesic effect in patients with chronic neuropathic pain, but there is limited data supporting the efficacy of lidocaine across other chronic pain phenotypes. Our study aimed to evaluate the efficacy of a single infusion of intravenous lidocaine for pain relief and the impact on quality of life. We evaluated data from 74 patients with chronic pain who were treated with intravenous lidocaine at a specialist pain centre. Participants completed a questionnaire consisting of the Brief Pain Inventory (BPI) Short Form and additional EQ-5D quality of life metrics, before treatment and at follow-up.

Data comparing pain severity did not demonstrate a statistically significant change after treatment when averaged across the entire patient cohort (6.15–5.88, p = .106), irrespective of gender or pain phenotype. Scores for pain interference showed statistically significant reductions following treatment (7.05–6.41, p = .023), which may have been driven through improvements in sleep (7.41–6.35, p = .001); however, these reductions are not clinically significant.

The patient cohort was stratified into responders and non-responders based on >30% improvement in response to an overall impression of pain reduction question following treatment. In the ‘responder’ cohort, pain intensity scores showed a statistically significant reduction post-infusion (6.18–5.49, p = .0135), but no change was apparent for non-responders (6.07–6.09, p = .920). There were no differences between responders and non-responders for pain sub-types in our study.

This study found no difference in pain outcomes in a cohort of patients with chronic pain, a mean of 63 days following a single lidocaine infusion. However, a specific subgroup of responders may show slight improvements in some pain outcomes that may warrant further exploration.

1. Fayaz, A, Croft, P, Langford, RM, et al. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open. 2016;6(6):e010364. Doi: 10.1136/bmjopen-2015-010364.
Google Scholar | Crossref | Medline2. Bevers, K, Watts, LF, Gatchel, R. The biopsychosocial model of the assessment, prevention, and treatment of chronic pain. US Neurol. 2016;12(2):98–104. Doi: 10.17925/USN.2016.12.02.98.
Google Scholar | Crossref3. Treede, R-D, Rief, W, Barke, A, et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain. 2019;160(1): 19–27. https://journals.lww.com/pain/Fulltext/2019/01000/Chronic_pain_as_a_symptom_or_a_disease__the_IASP.3.aspx.
Google Scholar | Crossref | Medline4. Kandil, E, Melikman, E, Adinoff, B. Lidocaine infusion: a promising therapeutic approach for chronic pain. J Anesth Clin Res. 2017;8(1):697. Doi: 10.4172/2155-6148.1000697.
Google Scholar | Crossref | Medline5. Moulin, D, Boulanger, A, Clark, AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328–335. Doi: 10.1155/2014/754693.
Google Scholar | Crossref | Medline6. Yousefshahi, F, Predescu, O, Francisco Asenjo, J. The efficacy of systemic lidocaine in the management of chronic pain: a literature review. Anesthesiol Pain Med. 2017;7(3):e44732. Doi: 10.5812/aapm.44732.
Google Scholar | Crossref | Medline7. Masic, D, Liang, E, Long, C, et al. Intravenous lidocaine for acute pain: a systematic review. Pharmacotherapy. 2018;38(12):1250–1259.
Google Scholar | Crossref | Medline8. Kastrup, J, Petersen, P, Dejgård, A, et al. Intravenous lidocaine infusion: a new treatment of chronic painful diabetic neuropathy? Pain. 1987;28(1):69–75. Doi: 10.1016/0304-3959(87)91061-x.
Google Scholar | Crossref | Medline9. National Institute for Health and Care Excellence (NICE) (2021) Chronic Pain (Primary and Secondary) in over 16s: Assessment and Management of Chronic Primary. Available at: https://www.nice.org.uk/guidance/ng193/resources/chronic-pain-primary-and-secondary-in-over-16s-assessment-of-all-chronic-pain-and-management-of-chronic-primary-pain-pdf-66142080468421 (accessed 15 August).
Google Scholar10. Wren, K, Lancaster, RJ, Hudson, A, et al. Intravenous lidocaine for relief of chronic neuropathic pain. AANA J. 2019;87(5):351–355.
Google Scholar | Medline11. Wilderman, I, Pugacheva, O, Perelman, V, et al. Repeated intravenous lidocaine infusions for patients with fibromyalgia: higher doses of lidocaine have a stronger and longer-lasting effect on pain reduction. Pain Med. 2020;21(6):1230–1239. Doi: 10.1093/pm/pnz251.
Google Scholar | Crossref | Medline12. Moulin, DE, Morley-Forster, PK, Pirani, Z, et al. Intravenous lidocaine in the management of chronic peripheral neuropathic pain: a randomized-controlled trial. Can J Anesth Can d’anesthésie. 2019;66(7):820–827. Doi: 10.1007/s12630-019-01395-8.
Google Scholar | Crossref | Medline13. Kim, Y-C, Castañeda, AM, Lee, C, et al. Efficacy and safety of lidocaine infusion treatment for neuropathic pain: a randomized, double-blind, and placebo-controlled study. Reg Anesth Pain Med. 2018;43(4):415–424. Doi: 10.1097/AAP.0000000000000741.
Google Scholar | Crossref | Medline14. Zhu, B, Zhou, X, Zhou, Q, et al. Intra-venous lidocaine to relieve neuropathic pain: a systematic review and meta-analysis. Front Neurol. 2019;10:954. https://www.frontiersin.org/article/10.3389/fneur.2019.00954.
Google Scholar | Crossref | Medline15. https://www.nice.org.uk/guidance/ng193/chapter/Recommendations
Google Scholar16. Haanpää, M, Attal, N, Backonja, M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152(1):14–27. Doi: 10.1016/j.pain.2010.07.031.
Google Scholar | Crossref | Medline | ISI